Skip to Content


PDF options:  View Fullscreen   Download PDF

PDF Transcript



Bleeding and prevention of bleeding during vitamin K antagonist treatment:
The dose will depend on the Internal normalised ratio (INR) before treatment and the targeted INR. In the following table approximate doses (ml/kg body weight of the reconstituted
product) required for normalisation of INR (≤ 1.2 within 1 hour) at different initial INR levels
are given.
Initial INR

2 – 2.5

2.5 – 3

3 – 3.5

> 3.5

Approximate dose* (ml
Octaplex/kg body weight)

0.9 –1.3

1.3 – 1.6

1.6 – 1.9

> 1.9

Octaplex 1000 IU

powder and solvent for solution for infusion
Human prothrombin complex
Read all of this leaflet carefully before you start using this medicine because it
contains important information for you.
• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor, pharmacist or nurse.
• This medicine has been prescribed for you only. Do not pass it on to others. It may harm
them, even if their signs of illness are the same as yours.
• If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any
possible side effects not listed in this leaflet. See section 4.

*The single dose should not exceed 3,000 IU (= 120 ml Octaplex).

As these recommendations are empirical and recovery and the duration of effect may vary,
monitoring of INR during treatment is mandatory.
Bleeding and perioperative prophylaxis in congenital deficiency of the vitamin K dependent
coagulation factors II and X when specific coagulation factor product is not available:
The calculated required dosage for treatment is based on the empirical finding that approximately 1 IU of factor II or X per kg body weight raises the plasma factor II or X activity by 0.02
and 0.017 IU/ml, respectively.
• Required units = body weight (kg) x desired factor X rise (IU/ml) x 59
where 59 (ml/kg) is the reciprocal of the estimated recovery.
• Required dosage for factor II:
Required units = body weight (kg) x desired factor II rise (IU/ml) x 50
If the individual recovery is known that value should be used for calculation.
Instructions for reconstitution:
1. If necessary, allow the solvent (Water for Injections) and the powder in the closed vials
to reach room temperature. This temperature should be maintained during reconstitution.
If a water bath is used for warming, care must be taken to avoid water coming into contact
with the rubber stoppers or the caps of the vials. The temperature of the water bath should
not exceed 37°C.
2. Remove the caps from the powder vial and the water vial and clean the rubber stoppers
with an alcohol swab.
3. Peel away the lid of the outer package of the Mix2Vial™. Place the solvent vial on an even
surface and hold it firmly. Place the blue part of the Mix2Vial™ on top of the solvent vial
and press firmly down until it snaps (Fig. 1). While holding onto the solvent vial, carefully
remove the outer package from the Mix2Vial™, being careful to leave the Mix2Vial™
attached firmly to the solvent vial (Fig. 2).
4. Place the powder vial on an even surface and hold it firmly. Take
the solvent vial with the attached Mix2Vial™ and turn it upside
down. Place the transparent part on top of the powder vial and
press firmly down until it snaps (Fig. 3). The solvent flows automatically into the powder vial.


Fig. 1

Fig. 2

Fig. 3

Fig. 4

5. With both vials still attached, gently swirl the powder vial until the product is dissolved.
Octaplex dissolves quickly at room temperature to a colourless to slightly blue solution.
Unscrew the Mix2Vial™ into two parts (Fig. 4).
Dispose the empty solvent vial with the blue part of the Mix2Vial™.
If the powder fails to dissolve completely or an aggregate is formed, do not use the preparation.
Instructions for infusion:
As a precautionary measure, the patients pulse rate should be measured before and during the
infusion. If a marked increase in the pulse rate occurs the infusion speed must be reduced or
the administration must be interrupted.
1. Attach a 40 ml syringe to the transparent part of the Mix2Vial™. Turn the vial upside down
and draw the solution into the syringe.
Once the solution has been transferred, firmly hold the plunger of the syringe (keeping it
facing down) and remove the syringe from the Mix2Vial™.
Dispose the Mix2Vial™ and the empty vial.
2. Disinfect the intended injection site with an alcohol swab.
3. Inject the solution intravenously at a slow speed: Initially 1 ml per minute, not faster than
2 – 3 ml per minute.
No blood must flow into the syringe due to the risk of formation of fibrin clots. The Mix2Vial™
is for single use only.


What is in this leaflet
1. What Octaplex is and what it is used for
2. What you need to know before you use Octaplex
3. How to use Octaplex
4. Possible side effects
5. How to store Octaplex
6. Contents of the pack and other information

Octaplex belongs to a group of medicines called clotting factors. It contains the human vitamin K dependent blood coagulation factors II, VII, IX and X.
Octaplex is used to treat and prevent bleeding:
• caused by medicines called vitamin K antagonists (such as warfarin). These medicines
block the effect of vitamin K and cause a shortage of the vitamin K dependent clotting
factors in your body. Octaplex is used when rapid correction of the shortage is required.
• in people born with a shortage of the vitamin K dependent clotting factors II and X. It is
used when purified specific clotting factor product is not available.

Octaplex must not be used:
• if you are allergic to one of the ingredients of this product (listed in section 6).
• if you are allergic to heparin or if heparin has ever caused a reduction in the level of
platelets in your blood.
Warnings and precautions
• Take the advice of a doctor who specialises in clotting disorders, when receiving Octaplex.
• If you have an acquired deficiency of the vitamin K dependent clotting factors (for example

caused by treatment with vitamin K antagonist medicines), Octaplex
should only be used when rapid correction of the shortage is necessary
such as major bleeding or emergency surgery. In other cases, lowering
the dose of the vitamin K antagonist medicine and/or administration
of vitamin K is usually sufficient.
If you receive a vitamin K antagonist medicine (like warfarin) you may have an increased risk of forming blood clots. In this case, treatment with Octaplex may enhance
the risk.
If you have been born with a shortage of any of the vitamin K dependent factors, specific coagulation factor product should be used when available.
If an allergic or anaphylactic- type reaction occurs, your doctor will stop the infusion
immediately and give appropriate treatment.
There is a risk of thrombosis or disseminated intravascular coagulation (serious illness,
with clots forming all over the body) when you receive Octaplex (particularly if you receive it regularly).You should be observed closely for signs or symptoms of intravascular
coagulation or thrombosis.
This is especially important if you have a history of coronary heart disease, liver disease,
if you are going to have an operation and also if Octaplex is given to very small babies
No data are available regarding the use of Octaplex in case of bleeding during the birth
due to vitamin K deficiency in the new born.

Viral Safety
• When medicines are made from human blood or plasma, certain measures are put in place
to prevent infections being passed on to patients. These include careful selection of blood
and plasma donors to make sure those at risk of carrying infections are excluded, and the
testing of each donation and pools of plasma for signs of virus/infections. Manufacturers
of these products also include steps in the processing of the blood or plasma that can inactivate or remove viruses. Despite these measures, when medicines prepared from human
blood or plasma are administered, the possibility of passing on infection cannot be totally
excluded. This also applies to any unknown or emerging virus or other types of infections.
The measures taken are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus. The measures taken may
be of limited value against non-enveloped viruses such as hepatitis A virus and parvovirus
B19. Parvovirus B19 infection may be serious for pregnant women (foetal infection) and
for individuals whose immune system is depressed or who suffer from a type of anaemia
(e.g. sickle cell disease or haemolytic anaemia).
It is strongly recommended that every time you receive a dose of Octaplex, the name and
batch number of the product are recorded in order to maintain a link to the batches used.
• Appropriate vaccination (hepatitis A and B) is recommended for you if you receive human
plasma-derived prothrombin complex products regularly/repeatedly.
Other medicines and Octaplex
Octaplex must not be mixed with other medicinal products.




Octaplex stops the effect of vitamin K antagonist medicines (like Warfarin), but no interactions
with other medicines are known.
Octaplex may affect the results of clotting tests which are sensitive to heparin.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other

Immune system problems:
Rare (more than 1 of 10,000, but less than 1 of 1,000 patients)
Rarely, patients treated with Octaplex for replacement therapy may develop neutralising antibodies (inhibitors) against any of the contained clotting factors. If such inhibitors occur, the
replacement therapy will not be very effective.

Pregnancy and breast-feeding
Octaplex should only be used during pregnancy and breast-feeding if clearly needed. Ask your
doctor or pharmacist for advice before taking any medicine.

General problems
Rare (more than 1 of 10,000, but less than 1 of 1,000 patients)
Increase in body temperature (fever) has not been observed but may rarely occur.

Driving and using machines
It is not known how Octaplex affects the ability to drive and use machines.
Important information about some of the ingredients of Octaplex
• Heparin may cause allergic reactions and reduced blood cell counts which may affect the
blood clotting system. Patients with a history of allergic reactions caused by heparin should
not use heparin-containing medicines.
• Octaplex contains 150 – 250 mg sodium per vial. To be taken into consideration by patients
on a controlled sodium diet.

Treatment with Octaplex should be started under the supervision of a doctor who is specialised in clotting disorders.
• First, the powder is dissolved in water
• Then the solution is given into a vein (the intravenous route).
How much Octaplex you receive, and for how long, depends on:
• how serious your illness is;
• where the bleeding is and how severe it is, and
• your general condition.

Vascular disorders
There is a risk of blood clotting following the administration of this medicine.
Nervous system disorders
Rare (more than 1 of 10,000, but less than 1 of 1,000 patients)
Headache may rarely occur.
Rare (more than 1 of 10,000, but less than 1 of 1,000 patients)
A temporary increase in liver test results (transaminases) has been rarely observed.
The heparin in the preparation may cause a sudden fall in the number of platelets in the blood.
This is an allergic reaction called “heparin-induced thrombocytopenia type II”. In rare cases in
patients not previously hypersensitive to heparin, this fall in the number of platelets can occur
6–14 days after the start of treatment. In patients with a previous heparin hypersensitivity, this
alteration may develop within a few hours of starting treatment.
The treatment with Octaplex must be stopped immediately in patients showing this allergic
reaction. These patients must not receive heparin containing medicinal products in the future.
For information on viral safety see section 2.

If you got more Octaplex than you should
In case of overdose, the risk is higher of developing
• clotting complications (such as heart attack and clots in your veins or lungs)
• disseminated intravascular coagulation (a serious illness where clots form all over the

Reporting of suspected adverse reactions
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via By reporting side effects you can help provide more information on the safety of this medicine.



Like all medicines, this medicine can cause side effects, although not
everybody gets them.

Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label. The expiry date
refers to the last day of that month.
Do not store above 25 °C. Do not freeze. Store in the original package in order to protect
from light.

Allergic reactions
Some patients may have allergic type reactions and fever.


The powder should be dissolved only directly before injection. The stability of the solution has
been demonstrated for up to 8 hours at +25°C. Nevertheless, to prevent contamination, the
solution should be used immediately and on one occasion only.

What Octaplex contains, per vial and after reconstitution with 40 ml solvent
The active substances are:
Name of ingredient
Total protein:
Active substances
Human coagulation factor II
Human coagulation factor VII
Human coagulation factor IX
Human coagulation factor X
Further active ingredients
Protein C
Protein S

Quantity per vial Quantity per ml reconstituted solution
520 – 1640 mg
13 – 41 mg/ml
560 – 1520 IU
360 – 960 IU
1000 IU
720 – 1200 IU

14 – 38 IU/ml
9 – 24 IU/ml
25 IU/ml
18 – 30 IU/ml

520 – 1240 IU
480 – 1280 IU

13 – 31 IU/ml
12 – 32 IU/ml

Octapharma Pharmazeutika Produktionsges.m.b.H.
Oberlaaer Str. 235, 1100 Vienna, Austria
This medicinal product is authorised in the Member States of the EEA under the
following names:
Austria, Belgium, Bulgaria, Denmark, Estonia, Finland, France, Germany, Greece, Hungary,
Iceland, Ireland, Latvia, Lithuania, Luxembourg, The Netherlands, Norway, Poland, Portugal,
Republic of Slovenia, Slovak Republic, Spain, United Kingdom: Octaplex
Czech Republic, Sweden: Ocplex
Italy, Romania: Pronativ

The specific activity of the product is ≥ 0.6 IU/mg proteins, expressed as factor IX activity.

This leaflet was last revised in 07/2015.

The other ingredients are:
Heparin, tri-sodium citrate dihydrate, Water for Injections.


What Octaplex looks like and contents of the pack
Octaplex is presented as a powder and solvent for solution for infusion.
Octaplex is sold in one carton containing
• 1 vial with powder for solution for infusion
• 1 vial with the solvent, 40 ml Water for Injections
• 1 transfer set Mix2Vial
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder:
Octapharma Limited
The Zenith Building, 26 Spring Gardens, Manchester M2 1AB, United Kingdom
For any further information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder:
Octapharma Limited
The Zenith Building, 26 Spring Gardens, Manchester M2 1AB, United Kingdom

General information about how to use Octaplex is provided in section 3.
The following information is intended for medical or healthcare professionals only:
Instructions for Treatment
Please read all the instructions and follow them carefully.
During the procedure described below, aseptic technique must be maintained.
The product reconstitutes quickly at room temperature.
The reconstituted solution should be clear or slightly opalescent.
Do not use solutions that are cloudy or have deposits.
Reconstituted products should be inspected visually for particulate matter and discoloration
prior to administration.
After reconstitution the solution must be used immediately.
Any unused product or waste material should be disposed of in accordance with local requirements.





+ Expand Transcript

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.